CoChat

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Open access
Apperloo, Ellen M., Gorriz, Jose L., Soler, Maria Jose, Cigarrán Guldris, Secundino, Cruzado, Josep M., Puchades, Maria Jesús, López-Martínez, Marina, Waanders, Femke, Laverman, Gozewijn D., van der Aart-van der Beek, Annemarie, Hoogenberg, Klaas, van Beek, André P., Verhave, Jacobien, Ahmed, Sofia B., Schmieder, Roland E., Wanner, Christoph, Cherney, David Z. I., Jongs, Niels, Heerspink, Hiddo J. L. · 2025 · Nature Medicine

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Abstract

Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind clinical trial in adults with CKD (estimated glomerular filtration rate (eGFR) ≥25 ml min-1 1.73 m-2 and urine albumin-to-creatinine ratio (UACR) ≥30 and <3,500 mg g-1) and body mass index ≥27 kg m-2. Participants were randomized to semaglutide 2.4 mg per week or placebo. The primary endpoint was percentage change from baseline in UACR at week 24. Safety was monitored throughout. Overall, 125 participants were screened, of whom 101 were randomized to semaglutide (n = 51) or placebo (n = 50). Mean age was 55.8 (s.d. 12) years; 40 participants (39.6%) were female; median UACR was 251 mg g-1 (interquartile range 100, 584); mean eGFR was 65.0 (s.d. 25) ml min-1 1.73 m-2; and mean body mass index was 36.2 (s.d. 5.6) kg m-2. Chronic glomerulonephritis (n = 25) and hypertensive CKD (n = 27) were the most common CKD etiologies. Treatment for 24 weeks with semaglutide compared to placebo reduced UACR by -52.1% (95% confidence interval -65.5, -33.4; P < 0.0001). Gastrointestinal adverse events were more often reported with semaglutide (n = 30) than with placebo (n = 15). Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. ClinicalTrials.gov registration: NCT04889183 .

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03327-6

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 44 references

Cited by

See all 120

Metadata

Authors
Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., Hoogenberg, K., van Beek, A. P., Verhave, J., Ahmed, S. B., Schmieder, R. E., Wanner, C., Cherney, D. Z. I., Jongs, N., & Heerspink, H. J. L.
Affiliations
  • University Medical Center Groningen (NL)
  • Bellvitge University Hospital (ES)
  • Vall d'Hebron Institut de Recerca (ES)
  • Isala (NL)
  • Ziekenhuis Groep Twente (NL)
  • Martini Ziekenhuis (NL)
  • Rijnstate Hospital (NL)
  • University of Alberta (CA)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Universitätsklinikum Würzburg (DE)
  • University of Toronto (CA)
Corresponding author
Heerspink, Hiddo J. L.
Venue
Nature Medicine
Published
2024-10-25
Volume
31
Issue
1
Pages
278-285
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4403750647
Cited by
120
References
45
Citations by year
2026: 51 · 2025: 64 · 2024: 5
FWCI
34.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
semaglutide, obesity, overweight, chronic kidney disease, albuminuria, albumin-creatinine ratio, GIP/GLP-1 receptor agonist, weight loss, systolic blood pressure, gastrointestinal adverse effects, non-diabetic CKD, kidney disease progression, body mass index, estimated glomerular filtration rate, chronic glomerulonephritis
MeSH terms
Semaglutide, Adult, Aged, Albuminuria, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Obesity, Body Mass Index, Overweight, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1038/s41591-024-03327-6
The paper
Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., Hoogenberg, K., van Beek, A. P., Verhave, J., Ahmed, S. B., Schmieder, R. E., Wanner, C., Cherney, D. Z. I., Jongs, N., & Heerspink, H. J. L. (2025). Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03327-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.